Categories

Most recent posts

  XML Feeds

Search

« Emergency Care In Ohio Cities Ranks Among Best In NationStudy: Earlier Mammograms Benefit Breast Cancer Patients »

FDA Advisory Committee Favors Approval Of Weight-Loss Drug

02/23/12

  10:36:01 am, by MedBen5   , 153 words,  
Categories: News, Prescription, Wellness

FDA Advisory Committee Favors Approval Of Weight-Loss Drug

A follow-up to a post earlier this week: A advisory committee to the Food and Drug Administration recommended approval of the weight-loss drug Qnexa by a vote of 20 to 2, the New York Times reports.

The overwhelming support for Qnexa came as something of a surprise, as concerns about potential risks of heart problems and birth defects had lead an earlier FDA advisory panel to reject it. But some of the same members who opposed it perviously said they were reassured this time that the drugmaker Vivus would take measures to minimize the risks, such as recommending that pregnant women not get the medication.

The committee was also swayed by the contention of Vivus and some obesity specialists that excessive weight carries its own set of risks.

The FDA is expected to decide whether to approve Qnexa by April 17. If approved, it would be the first new prescription drug to treat obesity in 13 years.

No feedback yet